HL22
HL22 is a harmaline derivative. HL22 significantly inhibits HCT116, MGC803 and MCF7 cancer cell lines, and inhibits MGC803 cell migration and monoclonal formation. The anti-cancer mechanism of HL22 is related to a variety of metabolic pathways and can be used in the study of cancer[1].
Product Specifications
UNSPSC
12352005
Target
Drug Derivative
Related Pathways
Others
Field of Research
Cancer
Smiles
COC1=CC=C2C(N(CCCCCN3C4=CC(OC)=CC=C4C5=C3C(C)=NCC5)C6=C2C=CN=C6C)=C1
Molecular Formula
C31H34N4O2
Molecular Weight
494.63
References & Citations
[1]Liu Y, et al. Synthesis of harmaline N-9 derivatives and investigation of in vitro anticancer activity. Bioorg Med Chem Lett. 2025 Jan 13;119:130106.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15131545 1 Vial
Lentiviral mouse Vmn1r44 shRNA (UAS) - Lentiviral mouse Vmn1r44 shRNA (UAS, RFP) plasmid
Ask
View Details ![Rabbit Polyclonal FUNDC1 Antibody [HRP]](https://cdn.genprice.uk/genprice/uk/genprice5.webp)
132285-ML650 100 µL
RALBP1 (RLIP1, RLIP76, RalA-binding Protein 1, 76kD Ral-interacting Protein, Dinitrophenyl S-glutathione ATPase, DNP-SG ATPase, Ral-interacting Protein 1) (MaxLight 650)
Ask
View Details